Sept. 3, 2013
/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that
, CEO, will present at the 15
Annual Rodman & Renshaw Global Investment Conference, sponsored by
& Co., LLC. Mr. Riley is scheduled to present at
12:05 p.m. (Eastern Time)
Monday, September 9, 2013
at the Millennium Broadway Hotel in
New York City
A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at
. After the presentation, a replay will be archived and accessible for 30 days at the same website.
Mr. Riley, as well as Synthetic Biologics' CFO,
C. Evan Ballantyne
, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link
. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of
infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and
infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at
To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your
iPhone and iPad
Android mobile device
SOURCE Synthetic Biologics, Inc.